These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35383121)

  • 1. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.
    Boekel L; Hooijberg F; Vogelzang EH; Besten YR; Leeuw M; Atiqi S; van Vollenhoven RF; Wijbrandts CA; Gerritsen M; Krieckaert C; Dijkshoorn B; Bakhlakh S; Crooijmans JJ; Voskuyl A; van der Horst-Bruinsma IE; Lems W; Kuijpers TW; van Ham SM; Wieske L; Eftimov F; Kummer LY; van Dam PK; Stalman EW; Steenhuis M; Keijzer S; Cristianawati O; Keijser J; Loeff FC; Tas SW; Nurmohamed MT; Boers M; Rispens T; Wolbink G
    RMD Open; 2022 Apr; 8(1):. PubMed ID: 35383121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands.
    Boekel L; Atiqi S; Leeuw M; Hooijberg F; Besten YR; Wartena R; Steenhuis M; Vogelzang E; Webers C; Boonen A; Gerritsen M; Lems WF; Tas SW; van Vollenhoven RF; Voskuyl AE; van der Horst-Bruinsma I; Nurmohamed M; Rispens T; Wolbink G
    Lancet Rheumatol; 2023 Jul; 5(7):e375-e385. PubMed ID: 37398978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
    Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
    Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
    Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
    Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
    Boekel L; Steenhuis M; Hooijberg F; Besten YR; van Kempen ZLE; Kummer LY; van Dam KPJ; Stalman EW; Vogelzang EH; Cristianawati O; Keijzer S; Vidarsson G; Voskuyl AE; Wieske L; Eftimov F; van Vollenhoven R; Kuijpers TW; van Ham SM; Tas SW; Killestein J; Boers M; Nurmohamed MT; Rispens T; Wolbink G
    Lancet Rheumatol; 2021 Nov; 3(11):e778-e788. PubMed ID: 34396154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
    Álvaro Gracia JM; Sanchez-Piedra C; Manero J; Ruiz-Lucea ME; López-Vives L; Bohorquez C; Martinez-Barrio J; Bonilla G; Vela P; García-Villanueva MJ; Navío-Marco MT; Pavía M; Galindo M; Erausquin C; Gonzalez-Gay MA; Rua-Figueroa I; Pego-Reigosa JM; Castrejon I; Sanchez-Costa JT; González-Dávila E; Diaz-Gonzalez F;
    RMD Open; 2021 Dec; 7(3):. PubMed ID: 34887346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease.
    Shenoy P; Ahmed S; Shanoj KC; Shenoy V; Damodaran D; Menon AR; Alias B; SanjoSaijan ; Devakumar D; Babu ASS
    Clin Rheumatol; 2021 Nov; 40(11):4665-4670. PubMed ID: 34155573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.
    FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
    Ann Rheum Dis; 2021 Apr; 80(4):527-538. PubMed ID: 33268442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs.
    Yousefghahari B; Navari S; Sadeghi M; Soleimaniamiri S; Soleimaniamiri M; Heidari B; Babaei M; Ghodrati K; Guran A; Gholinia H
    Clin Rheumatol; 2021 Oct; 40(10):4309-4315. PubMed ID: 34052904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
    Favalli A; Favalli EG; Gobbini A; Zagato E; Bombaci M; Maioli G; Pesce E; Donnici L; Gruarin P; Biggioggero M; Curti S; Manganaro L; Marchisio E; Bevilacqua V; Martinovic M; Fabbris T; Sarnicola ML; Crosti M; Marongiu L; Granucci F; Notarbartolo S; Bandera A; Gori A; De Francesco R; Abrignani S; Caporali R; Grifantini R
    Front Immunol; 2022; 13():873195. PubMed ID: 35757699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases-An Interim Report from a Danish Prospective Cohort Study.
    Schreiber K; Graversgaard C; Petersen R; Jakobsen H; Bojesen AB; Krogh NS; Glintborg B; Hetland ML; Hendricks O
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062696
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
    Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
    Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.
    Shin YH; Shin JI; Moon SY; Jin HY; Kim SY; Yang JM; Cho SH; Kim S; Lee M; Park Y; Kim MS; Won HH; Hong SH; Kronbichler A; Koyanagi A; Jacob L; Smith L; Lee KH; Suh DI; Lee SW; Yon DK
    Lancet Rheumatol; 2021 Oct; 3(10):e698-e706. PubMed ID: 34179832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics, Prognostic Factors, and Outcomes of COVID-19 in Autoimmune Rheumatic Disease Patients: A Retrospective Case-Control Study from Astana, Kazakhstan.
    Rutskaya-Moroshan K; Abisheva S; Abisheva A; Amangeldiyeva Z; Vinnik T; Batyrkhan T
    Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336418
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
    Sengler C; Eulert S; Minden K; Niewerth M; Horneff G; Kuemmerle-Deschner J; Siemer C; Berendes R; Girschick H; Hühn R; Borte M; Hospach A; Emminger W; Armann J; Klein A; Kallinich T
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34312307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.
    Eder L; Croxford R; Drucker AM; Mendel A; Kuriya B; Touma Z; Johnson SR; Cook R; Bernatsky S; Haroon N; Widdifield J
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):317-325. PubMed ID: 34486829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.
    Favalli EG; Gobbini A; Bombaci M; Maioli G; Biggioggero M; Pesce E; Favalli A; Martinovic M; Fabbris T; Marchisio E; Bandera A; Gori A; Abrignani S; Grifantini R; Caporali R
    Front Med (Lausanne); 2022; 9():850858. PubMed ID: 35360719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.